Iambic Therapeutics filed a registration statement for an initial public offering of its common stock, according to a filing with the US Securities and Exchange Commission on Monday.
Underwriters have been granted a 30-day option to purchase additional shares.
Terms of the offering, including the number of shares and expected price range, were not yet disclosed.
The company has applied to list its shares on the Nasdaq Global Select Market under the symbol "IAM."
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.